The mechanisms of mucus hypersecretion in asthma are poorly understood, even though sputum production is a prominent symptom of asthma exacerbations, and mucus plugging of the airways is prominent in the airways of patients who die from acute severe asthma. Although goblet cell hyperplasia is a pathologic feature of animal models of asthma, and allergen-induced goblet cell degranulation causes airway obstruction in sensitized animals, the role of the goblet cell in the pathogenesis of mucus hypersecretion and airway obstruction in human asthma is not clear. We hypothesize that the phenotype of the airway epithelium in mild and moderate asthma is characterized by goblet cell hypertrophy and hyperplasia, placing these patients at risk for acute episodes of airway obstruction secondary to an exaggerated goblet cell degranulation response to stimuli such as allergen and viruses. We further hypothesize that overexpression of mucin genes in airway goblet cells is one mechanism for goblet cell hypertrophy and hyperplasia. We propose to test our hypotheses using rigorous methods of quantitative morphometry, in situ hybridization, and RT-PCR to quantify goblet cell size, goblet cell degranulation, and goblet cell expression of mucin genes in endobronchial biopsies obtained during bronchoscopy from healthy and asthmatic subjects. In addition, because the effects of current asthma treatments on goblet cells are unknown, and because there is a need for studies of specific treatments of goblet cell hyperplasia, we propose to begin to explore the treatment of goblet cell abnormalities in human asthma by examining the effects of inhaled corticosteroids on goblet cell hypersecretion, goblet cell mucin secretion, and goblet cell mucin gene expression.
Aim 1 will determine if mRNA levels for MUC-2 and MUC-5AC are higher than normal in goblet cells in the airway epithelium of asthmatic subjects.
Aim 2 will determine if goblet cell degranulation occurs in asthmatic subjects following allergen challenge.
Aim 3 will determine if treatment with an inhaled corticosteroid decreases mucin stores in goblet cells, mucin secreted on the airway epithelial surface, and mucin mRNA levels in endobronchial biopsies. The proposed studies address an unmet need, because few studies have been published focusing on goblet cells in human asthma. The application of the methods described here provide the opportunity to begin to understand the relationship between goblet cell hypersecretion and airway obstruction in human asthma, and may suggest strategies for improving treatment.
|Reber, Laurent L; Fahy, John V (2016) Mast cells in asthma: biomarker and therapeutic target. Eur Respir J 47:1040-2|
|Hays, S R; Ferrando, R E; Carter, R et al. (2005) Structural changes to airway smooth muscle in cystic fibrosis. Thorax 60:226-8|
|Woodruff, Prescott G; Dolganov, Gregory M; Ferrando, Ronald E et al. (2004) Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 169:1001-6|
|Ferrando, Ronald E; Nyengaard, Jens R; Hays, Steven R et al. (2003) Applying stereology to measure thickness of the basement membrane zone in bronchial biopsy specimens. J Allergy Clin Immunol 112:1243-5|
|Fahy, John V (2002) Goblet cell and mucin gene abnormalities in asthma. Chest 122:320S-326S|
|Woodruff, P G; Khashayar, R; Lazarus, S C et al. (2001) Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 108:753-8|
|Ordonez, C L; Khashayar, R; Wong, H H et al. (2001) Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 163:517-23|
|Fahy, J V; O'Byrne, P M (2001) ""Reactive airways disease"". A lazy term of uncertain meaning that should be abandoned. Am J Respir Crit Care Med 163:822-3|
|Fahy, J V (2001) Remodeling of the airway epithelium in asthma. Am J Respir Crit Care Med 164:S46-51|
|Woodruff, P G; Fahy, J V (2001) Asthma: prevalence, pathogenesis, and prospects for novel therapies. JAMA 286:395-8|
Showing the most recent 10 out of 16 publications